PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21086135-7	2010	In addition, in cells induced to differentiate by ATRA or VD3, Nitroblue-tetrazolium (NBT) reduction and esterase activity, were blocked either by LY294002, a PI3K inhibitor, or by BIM, a PKC inhibitor, without affecting cell surface markers such as CD11b or CD14.	Nitroblue Tetrazolium	86-89	CD14 molecule	Homo sapiens	259-263	
12677525-3	2003	The ability of HL-60 cells to reduce nitroblue tetrazolium (NBT) was significantly increased after APC treatment for 72 h. In these differentiating HL-60 cells, cell surface differentiation markers CD11b (for myeloid cells) and CD14 (for monocytic cells) were detected in 90.3 % and 70.1 % of the cells, respectively.	Nitroblue Tetrazolium	37-58	CD14 molecule	Homo sapiens	228-232	
12677525-3	2003	The ability of HL-60 cells to reduce nitroblue tetrazolium (NBT) was significantly increased after APC treatment for 72 h. In these differentiating HL-60 cells, cell surface differentiation markers CD11b (for myeloid cells) and CD14 (for monocytic cells) were detected in 90.3 % and 70.1 % of the cells, respectively.	Nitroblue Tetrazolium	60-63	CD14 molecule	Homo sapiens	228-232	
18425640-2	1998	After incubation with 200 U/mL IL-12 for 48 h, DNA synthesis of FBL-3 cells in S phase decreased significantly; the expression of CD14 which is the specific marker of monocyte increased, the rate of NBT(+) cells was apparently higher than that of the untreated FBL-3 cells.	Nitroblue Tetrazolium	199-202	CD14 molecule	Homo sapiens	130-134